Boundless Bio, Inc. Common Stock Cash Flow Conversion Efficiency
Boundless Bio, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.20 Million) by net assets ($110.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Boundless Bio, Inc. Common Stock (2016–2024)
Cash flow conversion efficiency of Boundless Bio, Inc. Common Stock from 2016 to 2024. This chart illustrates how Boundless Bio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BOLD stock price and chart for real-time trading data and today's change.
Boundless Bio, Inc. Common Stock Cash Flow Conversion Ratio Explained
Boundless Bio, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Boundless Bio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Boundless Bio, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PetMed Express Inc
NASDAQ:PETS
|
-0.164x |
|
Medicenna Therapeutics Corp
TO:MDNA
|
-0.799x |
|
Sc Engineering
KO:023960
|
-0.308x |
|
Alara Resources Ltd
AU:AUQ
|
-2.204x |
|
Pamapol S.A.
WAR:PMP
|
-0.041x |
|
Korporacja KGL S.A.
WAR:KGL
|
0.109x |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
-0.048x |
|
Archtis Ltd
AU:AR9
|
-0.252x |
Annual Cash Flow Conversion Efficiency for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of Boundless Bio, Inc. Common Stock from 2016 to 2024. Review financial flexibility index of Boundless Bio, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $150.64 Million | $-60.84 Million | -0.404x | -209.54% |
| 2023-12-31 | $-127.08 Million | $-46.85 Million | 0.369x | -23.93% |
| 2022-12-31 | $-81.70 Million | $-39.60 Million | 0.485x | -20.38% |
| 2021-12-31 | $-38.19 Million | $-23.25 Million | 0.609x | +349.62% |
| 2018-12-31 | $442.75 Million | $-107.98 Million | -0.244x | +54.81% |
| 2017-12-31 | $156.60 Million | $-84.51 Million | -0.540x | -31.42% |
| 2016-12-31 | $119.37 Million | $-49.02 Million | -0.411x | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more